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Abstract
Genome-wide association studies (GWAS) have established a variant, rs10993994, on chromosome 10q11 as being
associated with prostate cancer risk. Since the variant is located outside of a protein-coding region, the target genes driving
tumorigenesis are not readily apparent. Two genes nearest to this variant, MSMB and NCOA4, are strong candidates for
mediating the effects of rs109939934. In a cohort of 180 individuals, we demonstrate that the rs10993994 risk allele is
associated with decreased expression of two MSMB isoforms in histologically normal and malignant prostate tissue. In
addition, the risk allele is associated with increased expression of five NCOA4 isoforms in histologically normal prostate
tissue only. No consistent association with either gene is observed in breast or colon tissue. In conjunction with these
findings, suppression of MSMB expression or NCOA4 overexpression promotes anchorage-independent growth of prostate
epithelial cells, but not growth of breast epithelial cells. These data suggest that germline variation at chromosome 10q11
contributes to prostate cancer risk by influencing expression of at least two genes. More broadly, the findings demonstrate
that disease risk alleles may influence multiple genes, and associations between genotype and expression may only be
observed in the context of specific tissue and disease states.
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Introduction
Variation at rs10993994 on chromosome 10q11 is associated
with prostate cancer risk [1–5]. The risk polymorphism is located
at the telomeric end of a 50 kilobase (kb) linkage disequilibrium
block and is within 60 base pairs (bp) of the transcription start site
of beta-microseminoprotein (MSMB). MSMB has been character-
ized as a tumor suppressor [6], and lower levels of its product,
PSP94, are associated with more aggressive forms of prostate
cancer [7]. MSMB has therefore been a target of recent
investigation into the mechanism of chromosome 10q-associated
risk. Reporter assays demonstrate that plasmids carrying the
rs10993994 risk allele (T) significantly decrease luciferase activity
compared with the wild-type allele (C) [8,9]. In addition, in 19
cancer cell lines of various tissue types expressing MSMB, those
carrying the TT genotype have decreased MSMB expression
relative to those carrying a C allele [9]. However, no study has
definitively linked MSMB expression to risk allele status in human
prostate tissue. A second gene, nuclear receptor co-activator 4
(NCOA4, also known as ARA70), is a ligand-dependent androgen
PLoS Genetics | www.plosgenetics.org 1 November 2010 | Volume 6 | Issue 11 | e1001204receptor co-activator [10,11] and is within 16 kb telomeric of
rs10993994. Given its proximity to the risk variant and its activity
in the prostate gland [12], NCOA4 has also been considered a
candidate gene involved in the mechanism of disease risk [8].
Gene expression is a heritable trait [13–16] and represents a
powerful avenue for connecting risk variants with their target
genes. Studies have demonstrated that variation at intergenic or
intronic disease-associated loci can act through gene regulatory
mechanisms [17–20]. Because regulatory elements can interact
with many genes [21], and since both MSMB and NCOA4 are
strong candidates for prostate cancer risk, we evaluated the
relationship between risk allele status and transcript abundance of
these genes across both normal and tumor prostate tissues. We also
tested the functional consequences of altering the expression levels
of these candidate genes in immortalized prostate epithelial cells.
Results
A total of 180 individuals of European ancestry were genotyped
for the rs10993994 polymorphism, and MSMB and NCOA4
mRNA levels were quantified in tissue isolated from radical
prostatectomy surgical specimens. Samples were derived from two
cohorts- the Gelb Center at Dana-Farber Cancer Institute (DFCI)
(N=121 – histologically normal and tumor prostate tissue) and the
Physicians’ Health Study (PHS) [22] (N=59 – prostate tumor
tissue only). In the DFCI cohort, transcript levels were measured
in both normal and tumor prostate tissue using a quantitative
competitive PCR strategy (Methods). Two MSMB and five NCOA4
isoforms annotated in the Ensembl database (build 52) were
evaluated (Figure 1A). Each isoform of MSMB and NCOA4 was
expressed in both normal and tumor prostatic tissue. Expression
levels of MSMB and NCOA4 transcripts were significantly higher in
normal compared with tumor tissue (p,0.0001), consistent with
previously published reports [23–25]. In the PHS cohort, only
tumor tissue was isolated from radical prostatectomy specimens.
For this cohort the probes used to measure expression captured
both MSMB isoforms and all but one of the NCOA4 isoforms.
The T (risk) allele is significantly associated with transcript levels
of both MSMB and NCOA4 in histologically normal prostate tissue
(N=84). While the T allele is associated with decreased expression
of both MSMB isoforms (p-value range, 0.0033–0.0042), it is
associated with increased expression of all five isoforms of NCOA4
(p-value range, 6.7610
27–0.0055) (Figure 1B). In tumor tissue,
MSMB retains its association with risk allele status (p-value range,
0.016–0.053, Figure 1C, Figure S1). NCOA4 expression levels,
however, are no longer associated with genotype in tumor tissue
(p.0.30, Figure 1C, Figure S1). The associations are specific to
the genes in this region. Expression levels of TIMM23, the next
closest gene to the risk locus and 1.4 kb telomeric to NCOA4, are
not correlated with genotype status in either normal or tumor
tissue. (p.0.30, Figure S2).
Because rs10993994 is not a risk allele in colon or breast cancers,
we reasoned that the association between genotype and disease-
relevant genes may be specific to prostate tissue and not observed
in other tissue types. If an association between genotype and
expression of MSMB or NCOA4 were observed in tissue other than
prostate, then that gene may be less likely to be involved in
prostate cancer risk. MSMB and NCOA4 expression levels were
measured in histologically normal colon (N=72) and breast
(N=56) tissue samples. While breast tissue expresses both genes,
colon tissue only expresses NCOA4. Unlike prostate tissue, neither
breast nor colon tissue demonstrates convincing or consistent
associations with genotype across isoforms (Figure S3).
To evaluate thefunctional implications ofthegeneticfindings,we
tested the effect of increasing NCOA4 and suppressing MSMB
expression levels in immortalized prostate epithelial cells (LHSAR)
[26]. Specifically, we assessed the ability of NCOA4 and MSMB to
promote anchorage-independent growth, a phenotype strongly
associated with cell transformation [27–30]. Suppression of MSMB
expression in LHSAR cells led to a significant increase in
anchorage-independent colony growth (p-values 0.0023–0.0001;
Figure 2A, Figure S4). Overexpression of NCOA4 in LHSAR cells
also resulted in robust anchorage-independent colony growth
(p-value 0.0074; Figure 2B, Figure S4). To assess whether these
alterations were specific for prostate epithelial cells, similar
functional studies were performed in immortalized human
mammary epithelial cells [31]. In contrast to what was observed
in prostate epithelial cells, manipulating expression levels of MSMB
or NCOA4 did not result in any consistently significant change in the
anchorage-independent growth in mammary epithelial cells (Figure
S5). Together, these observations implicate a role for both NCOA4
and MSMB in the transformation of prostate epithelial cells.
Discussion
Genetic data presented here demonstrate that the chromosome
10q11 prostate cancer risk locus is associated with decreased levels
of MSMB and increased levels of NCOA4 RNA expression.
Strikingly, the functional data fully corroborate the genetic data.
When MSMB is knocked down or NCOA4 is overexpressed in
immortalized prostate epithelial cells, the cells become anchorage
independent. Our data suggest that both MSMB and NCOA4
mediate prostate tumorigenesis, and this study is the first, to our
knowledge, to implicate these genes in actual human prostate
tissue. As expected in a cohort comprised of subjects who
underwent radical prostatectomy, a large majority of individuals
included in the analysis were diagnosed with low- or intermediate-
risk prostate cancer. Despite a relatively homogenous cohort, the
results presented here are likely generalizable to most prostate
cancer cases since rs10993994 appears to confer risk for all levels
of prostate cancer aggressiveness [1,3,32,33,34].
Author Summary
Family history has long been recognized as an important
risk factor for prostate cancer. Beginning in 2006,
researchers have identified several genetic variants that
are associated with prostate cancer risk. Intriguingly, the
majority of prostate cancer risk variants do not reside in
genes. Determining the genes involved in the develop-
ment of disease, therefore, has proved challenging. In this
study we interrogate a known prostate cancer risk poly-
morphism on chromosome 10—rs10993994. We report
that this variant is significantly associated with the RNA
expression levels of two genes—MSMB and NCOA4. When
these expression changes are modeled in a cell line,
prostate cells that were previously non-tumorigenic
acquire a property known as anchorage independence, a
characteristic of cancer cells. Notably, the prostate risk
variant is not associated with expression or functional
changes in breast or colon cells. In addition, the effects are
most pronounced in normal rather than tumor prostate
tissue. Overall, these findings help define the genes driving
prostate cancer risk at chromosome 10. More generally,
the discoveries demonstrate the importance of consider-
ing several target genes, as well as the importance of
cellular context (tissue type and histological state), in
future analyses of other genetic risk regions.
MSMB and NCOA4 Implicated in Prostate Cancer Risk
PLoS Genetics | www.plosgenetics.org 2 November 2010 | Volume 6 | Issue 11 | e1001204Figure 1. RNA expression of MSMB and NCOA4 in normal and tumor prostate tissue by rs10994994 genotype. A. Chromosome 10q11
with isoforms of MSMB and NCOA4 (Ensembl build 52). Primers for competitive PCR were designed to cross exon-exon boundaries depicted by
colored lines 1–2 (MSMB) and 1–5 (NCOA4). B. Expression in histologically normal prostate tissue (n=84). Each point represents absolute RNA
expression for one individual, normalized to three housekeeping genes. The top and bottom of the boxes within each graph represent the upper and
lower quartiles for expression at each genotype. The band inside each box marks the median value. P-value for each graph denotes the significance
for association between expression and genotype. C. Expression in prostate tumor tissue in the Dana-Farber Cancer Institute series (n=61).
doi:10.1371/journal.pgen.1001204.g001
Figure 2. Suppressing MSMB or overexpressing NCOA4 is associated with increased anchorage-independent growth of prostate
epithelial cells. A. Effects of suppressing MSMB with three independent shRNAs in LHSAR cells (p-values 0.0001; M6, 0.0023; M8, and 0.0001; M9).
The increase in anchorage-independent growth inversely correlates with the degree of MSMB suppression (Figure S4). B. Anchorage-independent
growth of LHSAR cells overexpressing NCOA4 and a control vector (p=0.0074).
doi:10.1371/journal.pgen.1001204.g002
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PLoS Genetics | www.plosgenetics.org 3 November 2010 | Volume 6 | Issue 11 | e1001204Similar to the 10q11 risk allele, other disease risk loci have been
shown to affect expression of more than one gene [17,34]. A
variant associated with systemic lupus erythematous at chromo-
some 8p23, for example, is associated with increased expression of
one gene (BLK) and decreased expression of another (C8orf13)i nB
cell lines [34]. As more genes underlying complex traits are
discovered, it may be that certain risk alleles mediate their effects
through multiple genes, or alternatively, that two risk variants in
tight linkage disequilibrium influence separate genes. The findings
at 10q11 highlight the importance of considering multiple genes
when analyzing GWAS results.
The findings at 10q11 also underscore the importance of
evaluating risk loci in a tissue-specific context [35]. It is
hypothesized that a fraction of non-protein coding risk alleles will
alter disease risk by regulating gene activity, and these variants
may exert their effects in a specific genetic and epigenetic context
[21,36]. In the present study, the 10q11 risk variant is associated
with transcript levels of MSMB and NCOA4 in primary prostate
tissue. In contrast, no convincing or consistent association is
observed in colon or breast tissue. Similarly, alteration of MSMB
and NCOA4 expression significantly affects anchorage-indepen-
dence of prostate but not breast epithelial cells. These findings may
have implications for future studies attempting to connect risk
alleles with target gene(s). Evaluation of GWAS findings will focus,
in part, on identifying the genes targeted by risk alleles, as these are
the genes likely to drive the trait under study. Our findings suggest
that this type of analysis should include evaluation of the tissue at
risk for disease, although it is entirely plausible that variants
associated with a particular disease may manifest their effects in
tissues other than target tissue.
Notably, associations between rs10993994 genotype and
expression of MSMB and NCOA4 are observed in histologically
normal prostate tissue, whereas in tumor tissue an association is
detected with only MSMB (albeit at an attenuated level relative to
the normal tissue). It is conceivable that increased expression of
NCOA4 is associated with tumor initiation, as reflected by its
association with risk in solely normal tissue, while decreased
expression of MSMB is associated with both tumor initiation and
maintenance or progression. More studies, however, will be
necessary before a general principle emerges.
Cellular context also appears to be an important determinant in
the functional analysis of candidate risk genes. This is illustrated by
comparing data in the present study to previous work involving
NCOA4. The characteristics of two NCOA4 isoforms, alpha and
beta, have been studied in functional assays. Upregulation of
NCOA4beta increases anchorage-independent growth [11], while
overexpression of NCOA4alpha inhibits growth in LNCaP cells
[37]. Functional analysis of immortalized prostate epithelial cells
presented here demonstrates increased colony growth in the setting
of an overexpressed alpha isoform (Figure 2). Distinctions between
the cell lines used in these studies may account for these divergent
results. LNCaP cells are derived from metastatic prostate lesions.
Immortalized prostate epithelial cells, on the other hand, are not
tumorigenic and differentiate in the presence of androgen [26],
suggesting that these cells are more closely related to normal
prostate epithelial cells.
The data presented here suggest that tissue type (in this case,
prostate versus non-prostate tissue) and cellular states (i.e., normal
versus tumor) are likely important factors in the evaluation of
complex trait loci. Chromatin context and differential use of gene
regulatoryelementsacrosstissues and disease states maybe the basis
forexpressioneffectsspecifictonormalprostatetissue [36].Itcanbe
difficult to accurately model these effects outside of the particular
genetic and epigenetic context of specific tissues. Luciferase reporter
assays, for example, are often utilized to define a relationship
between a polymorphism and a gene. Reporter assays cannot,
however, detect situations where a risk variant is associated with
opposing transcriptional effects on two loci, as observed with
rs10993994. An alternative explanation for the effects on the two
transcripts is that two separate variants in linkage disequilibrium are
responsible for the different transcriptional effects.
In contrast to Mendelian diseases, where resequencing protein-
coding regions often reveals the causal gene, common complex trait
allelesoften occur outside of protein-codingregions. As is the case at
10q11 and other loci [38,39], these alleles may be associated with
expression of nearby and/or distal candidate genes. There are also
situations in which associations with strong candidate genes,
however, cannot be established by measuring steady-state expres-
sion at a single point in time [19]. In order to better understand the
gene(s) involved in complex trait pathogenesis, experiments will
need to integrate and to account for the genetic and epigenetic
contexts of the particular tissue type and cellular state.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Dana-Farber Cancer Institute. All
patients provided written informed consent for the collection of
samples and subsequent analysis.
Cohorts and RNA isolation
A total of 180 patients treated with radical prostatectomy (RP)
for prostate cancer and 92 patients treated for colon cancer
consented to provide tissue. Additionally, histologically normal
breast tissue from 56 from women undergoing cosmetic reduction
surgery was analyzed in the present study.
Fresh frozen radical prostatectomy specimens were available
from 121 subjects at the Dana-Farber Cancer Institute (DFCI) and
Brigham and Women’s Hospital (Boston, MA) and were reviewed
by a pathologist (J.C. or R.F.). Over 95% of the patients in the
cohort were diagnosed with Gleason 6 or Gleason 7 disease and
median PSA was 5.1 ng/ml. Areas of tumor consisted of .60%
tumor cells and areas of benign tissue consisted of .80% non-
neoplastic epithelial cells at least 5 mm away from any tumor
focus. Biopsy cores of fresh frozen tissue were processed for RNA
extraction using a modified Qiagen Allprep DNA/RNA protocol.
Archival FFPE blocks were available for 59 men with prostate
cancer enrolled in the Physicians’ Health Study (PHS) [22,40].
These men were diagnosed with prostate cancer between 1983
and 2003 and treated by radical prostatectomy. RNA were
extracted from paraffin-embedded tumor tissue as described
previously [40]. Areas of tumor consisted of .90% tumor cells.
Fresh frozen colorectal cancer tissue samples were reviewed by a
pathologist (J.C.) and areas of benign tissue were selected where
80% of cells consisted of non-neoplastic epithelium. RNA was
extracted using a modified Qiagen Allprep DNA/RNA protocol.
Fresh frozen normal breast tissue samples were reviewed to
identify tissue blocks containing .40% normal epithelial cells.
RNA was extracted using a modified Qiagen RNeasy protocol.
Ethnicity was self-reported by most, but not all, subjects.
Subjects in the DFCI cohort of unknown ancestry were genotyped
for 59 ancestry-informative SNPs in order to ascertain ethnicity.
The marker set primarily captured ancestral differences between
European and African ancestries (D. Reich, personal communi-
cation). Five samples found to be from subjects of African ancestry
were excluded from analysis.
MSMB and NCOA4 Implicated in Prostate Cancer Risk
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treated at Brigham and Women’s Hospital, Dana-Farber Cancer
Institute or Vall d’Hebron University Hospital in Barcelona, Spain,
allof whom providedinformed consent. The studywasapprovedby
the Institutional Review Board at Dana-Farber Cancer Institute.
Expression analysis
cDNA was prepared for expression analysis using Invitrogen
SuperScript III Reverse Transcription kit. DFCI prostate samples,
colon samples and breast samples were analyzed via competitive
RT-PCR using Sequenom iPLEX matrix-assisted laser desorp-
tion/ionization (MALDI)-time of flight mass spectrometry tech-
nology. Expression levels of two MSMB isoforms and five NCOA4
isoforms were measured. These splice variants represent all
isoforms reported in Ensembl genebuild 52. RNA expression of
TIMM23 and three housekeeping genes (ACTB, MYL6 and
RPL13A) were also measured. Primer, probe and competitor oligo
sequences are available upon request. Reactions were performed
in quadruplicate using 8 serial dilutions of competitor, and the
EC50 was calculated using QGE Analyzer software (Sequenom).
The PHS subgroup was analyzed using Illumina cDNA-mediated
Annealing, Selection, Extension and Ligation (DASL) expression
assay (Illumina).
Expression data analysis
A gene expression normalization factor was calculated using the
geometric mean of expression level of the three housekeeping
genes. Linear regression was used to assess whether expression
levels increased (or decreased) as the number of T-alleles of
rs10993994 increased; for prostate tissue, differences between
prostate tumor and normal tissue levels were also assessed and
random effects linear regression was used to account for within-
sample correlation of tumor/normal pairs.
Genotyping
Genotyping of DNA from each subject was carried out using
Sequenom iPLEX matrix-assisted laser desorption/ionization
(MALDI)-time of flight mass spectrometry technology.
Cell culture
LHSAR: Prostate epithelial cells (PrECs) immortalized with
hTERT, SV40 Large T and small t antigens and overexpressing
androgen receptor were grown in PREGM (Lonza CC-3166).
HMLE: Human mammary epithelial cells immortalized with
hTERT, Large T and small t antigens were grown in MEGM
(Lonza CC-3150). All growth media were supplemented with
100 ug/ml Penicillin/Streptomycin.
Soft agar colony formation assay
Thebottomlayercontained0.6%agar(SigmaA5431)inDMEM
and 8% FBS. The top layer contained 0.3% agar in PREGM or
MEGM for LHSAR or HMLE respectively. Fifteen thousand cells
were seeded in the top agar layer in triplicate wells of a 6 well plate.
Colonies were counted from 2 to 6 weeks post-seeding. Image of
each well was taken at a 66magnification and analyzed with Image
J software. Colonies that were 50 sq. pixels or larger were counted.
Quantitative RT-PCR
Qiagen RNeasy kit was used for RNA extraction. Reverse
transcription was carried out with Clonetech Advantage RT-to-
PCR kit while the quantitative PCR was carried out using SYBR
Green Master Mix (Applied Biosystems). Two sets of NCOA4 and
one set of MSMB primers were used:
1) NCOA4 exon 3-4 - Forward CAGCAGCTCTACTCGT-
TATTGG
Reverse TCTCCAGGCACACAGA-
GACT
2) NCOA4 exon 5-6 - Forward CTCTCAAAACCATTCAA-
ATTCCT
Reverse CTCTGGCATGGAGAT-
ACAGC
3) MSMB exon 1-2 - Forward GCTTATCACAATGAATG-
TTCTCCT
Reverse AATCTCCTGGAACTCCC-
TCA
Expression constructs
NCOA4 expression constructs were received from the human
ORFeome V5.1 and cloned into pWZL-Neo retroviral expression
vector. Retrovirus production, infection and selection were carried
out as described previously [41].
RNA interference
Short hairpins in pLKO.1 lentiviral constructs were received
from the RNAi Consortium (TRC). Lentivirus production and
infection were carried out as described previously [42].
1) Hairpin shMSMB M6 TRC Clone ID TRCN0000147237
Target sequence GTTCTGTCAGTGAATGGATAA
2) Hairpin shMSMB M8 TRC Clone ID TRCN0000146396
Target sequence CACCTTCGTGACTTTATGCAA
3) Hairpin shMSMB M9 TRC Clone ID TRCN0000146343
Target sequence CAAAGGAAACAAACACCCAAT
Supporting Information
Figure S1 RNA expression of MSMB and NCOA4 in tumor
prostate tissue by genotype at rs10994994. Expression in prostate
tumor tissue in the Physicians’ Health Study series (n=59). Each
point represents absolute RNA expression for one individual. The
top and bottom of the boxes within each graph represent the
upper and lower quartiles for expression at each genotype. The
band inside each box marks the median value. P-value for
association with MSMB expression, 0.0073. P-value for associa-
tion with NCOA4 expression, 0.2671.
Found at: doi:10.1371/journal.pgen.1001204.s001 (0.50 MB
TIF)
Figure S2 Expression of TIMM23 at chromosome 10q11 is not
associated with genotype at rs10993994 in prostate tissue. A.
Expression in histologically normal prostate tissue (n=84,
p=0.3459). B. Expression in prostate tumor tissue in the Dana-
Farber Cancer Institute series (n=61, p=0.9939).
Found at: doi:10.1371/journal.pgen.1001204.s002 (9.46 MB TIF)
Figure S3 MSMB and NCOA4 expression in breast and colon
epithelial tissue. Expression of MSMB and NCOA4 isoforms are
not consistently associated with genotype at rs10993994 in breast
or colon epithelial tissue. A. Expression in histologically normal
breast tissue (n=56). P-values for association between genotype
and expression included within each graph. B. Expression in
histologically normal colon tissue (n=72).
Found at: doi:10.1371/journal.pgen.1001204.s003 (9.47 MB TIF)
Figure S4 Quantitative RT-PCR for the expression of MSMB
and NCOA4 in LHSAR cells. A. MSMB suppression with three
MSMB and NCOA4 Implicated in Prostate Cancer Risk
PLoS Genetics | www.plosgenetics.org 5 November 2010 | Volume 6 | Issue 11 | e1001204individual shRNAs (shMSMB M6, M8 and M9). B. NCOA4
overexpression.
Found at: doi:10.1371/journal.pgen.1001204.s004 (9.46 MB TIF)
Figure S5 Anchorage-independent growth in human mammary
epithelial cells. MSMB and NCOA4 expression levels do not
consistently affect anchorage-independent growth of human
mammary epithelial cells (HMLE). A. Suppression of MSMB by
three independent shRNAs (p-values 0.0949, 0.7482, and 0.0197).
B. NCOA4 overexpression (p=0.1012).
Found at: doi:10.1371/journal.pgen.1001204.s005 (9.46 MB TIF)
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